Antibodies and remdesivir used to treat Marburg virus in rhesus macaques
The combination of mAbs and remdesivir induced an 80 percent protection rate against Marburg virus in rhesus macaques, according to a new study.
List view / Grid view
The combination of mAbs and remdesivir induced an 80 percent protection rate against Marburg virus in rhesus macaques, according to a new study.
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
Simple Western™ is an automated capillary immunoassay that produces publication-ready data to meet the highest standards of data integrity and rigor.
Working with RNA requires rigorous nuclease contamination controls in place. Stock up on Nuclease-Free tubes tips and buffers #Back2Lab
Researchers have developed a technique utilising antibodies to tag disease-causing proteins, to treat the underlying causes of disease.
Researchers have shown antibodies induced by the Pfizer and Moderna vaccines are less effective at neutralising certain SARS-CoV-2 variants.
New podcast on SARS-CoV-2 molecular testing: From human sample analysis to Wastewater Surveillance.
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.
A new study has revealed that immunoglobulin-M antibodies recognise microvesicles, which are critical for the progression of thrombosis.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.